Alexis Ogdie-Beatty, MD, MSCE

faculty photo
Associate Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine

Contact information
3400 Spruce Street
5 White Building
Hospital of the University of Pennsylvania
Philadelphia, PA 19104-4283
Office: 215-662-2454
Fax: 215-662-4500
University of Minnesota, 2002.
Georgetown University School of Medicine, 2006.
University of Pennsylvania, 2012.
Permanent link

Description of Research Expertise

Psoriatic Arthritis, Axial Spondyloarthritis, Epidemiology, Pharmacoepidemiology

Selected Publications

Karmacharya P, Stull C, Stephens-Shields A, Husni ME, Scher JU, Craig E, Fitzsimmons R, Reddy SM, Magrey MN, Ogdie A, Walsh JA.: Responsiveness and minimal clinically important difference in patient-reported outcome measures among patients with psoriatic arthritis. Arthritis Care Res (Hoboken) Mar 2023.

Walsh JA, Ogdie A, Michaud K, Peterson S, Holdsworth EA, Karyekar CS, Booth N, Dalby CM, Chakravarty SD, Dennis N, Gossec L.: Impact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: findings from a real-world study in the United States and Europe. Joint Bone Spine 90: 105534, Jan 2023.

Kumthekar A, Pedro S, Michaud K, Ozen G, Katz P, Baker J, Ogdie A.: Physical activity habits among older adults living with rheumatic disease. J Rheumatol Jan 2023.

Eder L, Gladman DD, Mease P, Pollock RA, Luna R, Aydin SZ, Ogdie A, Polachek A, Gruben D, Cadatal MJ, Kinch C, Strand V.: Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension. RMD Open 2023.

Tillett W, Ogdie A, Passey A, Gorecki P.: Impact of psoriatic arthritis and comorbidities on ustekinumab outcomes in psoriasis: a retrospective, observational BADBIR cohort study. RMD Open 2023.

Ogdie A, Shaw Y, Almonte M, Maksabedian Hernandez EJ, Stolshek B, Michaud K.: Perspectives on Treatment Burden for Methotrexate and Tumor Necrosis Factor Inhibitors Among Patients With Psoriatic Arthritis and Rheumatoid Arthritis: A Qualitative Study. ACR Open Rheumatol 2023.

Haberman RH, MacFarlane KA, Catron S, Samuels J, Blank RB, Toprover M, Uddin Z, Hu J, Castillo R, Gong C, Qian K, Piguet V, Tausk F, Yeung J, Neimann AL, Gulliver W, Thiele RG, Merola JF, Ogdie A, Rahman P, Chakravarty SD, Eder L, Ritchlin CT, Scher JU.: Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial. BMJ Open 12: e063650, Dec 2022.

Ogdie A, Hwang M, Pedro S, Veeranki P, Yi E, Hass S, Michaud K.: Association between disability scores and opioid use in patients with psoriatic arthritis and ankylosing spondylitis. Rheumatology (Oxford) Dec 2022.

Bergman MJ, Zueger P, Patel J, Saffore CD, Topuria I, Cavanaugh C, Fang S, Clewell J, Ogdie A.: Clinical and Economic Benefit of Achieving Disease Control in Psoriatic Arthritis and Ankylosing Spondylitis: A Retrospective Analysis from the OM1 Registry. Rheumatol Ther Nov 2022.

Mease PJ, Ogdie A, Chakravarty SD, Shiff NJ, Lin I, McLean RR, Malley W, Spitzer RL, Kavanaugh A, Merola JF.: Clinical Characteristics of Registry Participants with Psoriatic Arthritis Initiating Guselkumab: An Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Drugs Real World Outcomes Oct 2022.

back to top
Last updated: 04/18/2023
The Trustees of the University of Pennsylvania